Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that ...
Lilly's Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% ...
Eli Lilly and Company LLY announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed ...
The American Diabetes Association has issued a guidance statement that cautions against using compounded versions of popular ...
Research shows an average weight loss of just 5% could save an annual $153bn in medical fees and lost productivity.
The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
Eli Lilly LLY recently announced its plans to spend $3 billion to expand the manufacturing facility in Wisconsin that was ...